
Plexus (PLXS) Stock Forecast & Price Target
Plexus (PLXS) Analyst Ratings
Bulls say
Plexus Corp's positive outlook is underpinned by a solid performance in its Health Care Life Sciences segment, which reported a revenue increase of 5% year-over-year for the full year, reaching $1.629 billion, with expectations of continued growth in the upcoming quarter. The Aerospace & Defense segment is anticipated to experience mid-single-digit growth quarter-over-quarter, driven by program ramp-ups and demand in both commercial air and defense sectors, aligning with the company's revenue growth goal of 9-12%. Furthermore, excluding the impact of restructuring charges, Plexus's earnings are projected to grow at nearly double the pace of revenue, indicating strong operational leverage as the company's strategic initiatives unfold.
Bears say
Plexus Corp has experienced a decline in gross margin from 10.1% to 9.9% in FQ4, indicating pressure on profitability, while revenue from the Aerospace & Defense segment fell by 6% both quarter-over-quarter and year-over-year. Furthermore, the company anticipates a decrease in Industrial revenues in the upcoming quarter, reflecting seasonal fluctuations and moderating demand, despite expectations for modest growth in fiscal year 2026. These financial challenges are compounded by broader economic concerns, such as signs of a global slowdown and potential disruptions in manufacturing, which add to Plexus's company-specific risks and competitive pressures.
This aggregate rating is based on analysts' research of Plexus and is not a guaranteed prediction by Public.com or investment advice.
Plexus (PLXS) Analyst Forecast & Price Prediction
Start investing in Plexus (PLXS)
Order type
Buy in
Order amount
Est. shares
0 shares